rs150031515
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -17 ACMG points: 0P and 17B. BP4_StrongBP6_Very_StrongBP7BS1
The NM_006030.4(CACNA2D2):c.1227C>T(p.Asp409Asp) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000892 in 1,613,978 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.00032 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000065 ( 0 hom. )
Consequence
CACNA2D2
NM_006030.4 synonymous
NM_006030.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -2.06
Publications
1 publications found
Genes affected
CACNA2D2 (HGNC:1400): (calcium voltage-gated channel auxiliary subunit alpha2delta 2) Calcium channels mediate the entry of calcium ions into the cell upon membrane polarization. This gene encodes the alpha-2/delta subunit of the voltage-dependent calcium channel complex. The complex consists of the main channel-forming subunit alpha-1, and auxiliary subunits alpha-2/delta, beta, and gamma. The auxiliary subunits function in the assembly and membrane localization of the complex, and modulate calcium currents and channel activation/inactivation kinetics. The subunit encoded by this gene undergoes post-translational cleavage to yield the extracellular alpha2 peptide and a membrane-anchored delta polypeptide. This subunit is a receptor for the antiepileptic drug, gabapentin. Mutations in this gene are associated with early infantile epileptic encephalopathy. Single nucleotide polymorphisms in this gene are correlated with increased sensitivity to opioid drugs. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2014]
CACNA2D2 Gene-Disease associations (from GenCC):
- cerebellar atrophy with seizures and variable developmental delayInheritance: AR Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
- complex neurodevelopmental disorderInheritance: AR Classification: MODERATE Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -17 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.8).
BP6
Variant 3-50379125-G-A is Benign according to our data. Variant chr3-50379125-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 416534.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-2.06 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.000322 (49/152328) while in subpopulation AFR AF = 0.000938 (39/41580). AF 95% confidence interval is 0.000705. There are 0 homozygotes in GnomAd4. There are 27 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CACNA2D2 | ENST00000424201.7 | c.1227C>T | p.Asp409Asp | synonymous_variant | Exon 12 of 38 | 1 | NM_006030.4 | ENSP00000390329.2 | ||
| CACNA2D2 | ENST00000423994.6 | c.1227C>T | p.Asp409Asp | synonymous_variant | Exon 12 of 39 | 5 | ENSP00000407393.2 | |||
| CACNA2D2 | ENST00000266039.7 | c.1227C>T | p.Asp409Asp | synonymous_variant | Exon 12 of 38 | 1 | ENSP00000266039.3 | |||
| CACNA2D2 | ENST00000360963.7 | c.1020C>T | p.Asp340Asp | synonymous_variant | Exon 12 of 38 | 1 | ENSP00000354228.3 |
Frequencies
GnomAD3 genomes AF: 0.000322 AC: 49AN: 152210Hom.: 0 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
49
AN:
152210
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.000143 AC: 36AN: 251118 AF XY: 0.000103 show subpopulations
GnomAD2 exomes
AF:
AC:
36
AN:
251118
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000650 AC: 95AN: 1461650Hom.: 0 Cov.: 33 AF XY: 0.0000468 AC XY: 34AN XY: 727102 show subpopulations
GnomAD4 exome
AF:
AC:
95
AN:
1461650
Hom.:
Cov.:
33
AF XY:
AC XY:
34
AN XY:
727102
show subpopulations
African (AFR)
AF:
AC:
53
AN:
33480
American (AMR)
AF:
AC:
3
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
26136
East Asian (EAS)
AF:
AC:
1
AN:
39700
South Asian (SAS)
AF:
AC:
1
AN:
86256
European-Finnish (FIN)
AF:
AC:
0
AN:
53272
Middle Eastern (MID)
AF:
AC:
2
AN:
5768
European-Non Finnish (NFE)
AF:
AC:
25
AN:
1111928
Other (OTH)
AF:
AC:
10
AN:
60388
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.479
Heterozygous variant carriers
0
6
12
17
23
29
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.000322 AC: 49AN: 152328Hom.: 0 Cov.: 33 AF XY: 0.000363 AC XY: 27AN XY: 74482 show subpopulations
GnomAD4 genome
AF:
AC:
49
AN:
152328
Hom.:
Cov.:
33
AF XY:
AC XY:
27
AN XY:
74482
show subpopulations
African (AFR)
AF:
AC:
39
AN:
41580
American (AMR)
AF:
AC:
5
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3472
East Asian (EAS)
AF:
AC:
0
AN:
5178
South Asian (SAS)
AF:
AC:
0
AN:
4832
European-Finnish (FIN)
AF:
AC:
0
AN:
10614
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
4
AN:
68034
Other (OTH)
AF:
AC:
1
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.509
Heterozygous variant carriers
0
3
7
10
14
17
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Developmental and epileptic encephalopathy Benign:1
Oct 28, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not provided Benign:1
Mar 27, 2018
Athena Diagnostics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Cerebellar atrophy with seizures and variable developmental delay Benign:1
Dec 19, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.